Author + information
- Anselm K. Gitta,b,
- Dominik Lautscha,b,
- Martin Horacka,b,
- Philippe Brudia,b,
- Larry Liua,b and
- Jean Ferrièresa,b
Background: Although chronic statin treatment is well established, LDL-Chol goal attainment (<70mg/dl) in very high risk patients has been low. Little is known, if LDL-Chol goal attainment in Europe and the Middle East has improved in 2013/14 versus 2008/09.
Methods: In 10 countries (Italy, France, Greece, Ireland, Belgium, Russia, Saudi Arabia, United Arab Emirates, Jordan and Lebanon) 8,820 patients with coronary heart disease (CHD) under chronic statin therapy were enrolled into DYSIS (in 2008-2009) and 4,000 patients into DYSIS II (in 2013-2014) to document LDL-C goal attainment (LDL-Chol < 70mg/dl). Data were collected under real life conditions in the outpatient setting. We examined the LDL-C goal achievement in those countries participating in both DYSIS studies.
Results: In DYSIS II (2013/14), patients were treated with more potent statins such as atorvastatin and rosuvastatin as well as with higher statin dose as compared to DYSIS (2008/09). In addition, more patients did receive ezetimibe in DYSIS II (table). More patients reached the LDL-Chol goal <70 mg/dl in DYSIS II as compared to DYSIS (29.8% vs 22.1%, p<0.05). These improvements were predominantly seen in Europe with large differences between the participating countries (figure).
Conclusions: We documented an improvement in LDL-Chol goal attainment <70mg/dl between 2008/9 and 2013/14 in Europe and Middle East. Despite this improvement, still more than two thirds of high risk patients don't achieve recommended LDL-Chol targets.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Advances in Cholesterol Measurement and Management
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1106-048
- 2017 American College of Cardiology Foundation